JERUSALEM--(BUSINESS WIRE)--Today Novellus, Ltd., a clinical-stage biotechnology company focused on precision oncology, and Tempus, a leader in artificial intelligence and precision medicine, announced their collaboration to accelerate patient enrollment for Novellus’ next generation BRAF inhibitor program.
Novellus’ BRAF program focuses on patient populations for which there are currently no FDA-approved BRAF inhibitors, including BRAF fusions and BRAF-mutated gliomas. Novellus will participate in Tempus’s TIME Trial® Network, and the companies will work together to identify relevant patients to accelerate patient enrollment.
“The collaboration with Tempus will enable us to accelerate the enrollment of patients in our BRAF trial, by precisely identifying potential candidates and opening sites wherever the patients are found” said Michael Vidne, Chief Executive Officer of Novellus.
“The TIME Trial Program has achieved an unparalleled scale thus far, with over 50 provider networks and 2,500 oncologists included in its network,” said Kim Blackwell, Chief Medical Officer of Tempus. “We’re excited to collaborate with Novellus, to further our mission to increase trial participation, and to ultimately bring the right treatment to the right patients at the right time.”
About Novellus, Ltd.
Novellus is a clinical-stage drug development company. Novellus focuses on the development of compounds for established oncogene drivers with a high incidence of uncharacterized mutations. Novellus’ BRAF program is in clinical trial (NCT02428712).
